Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05c7 trial

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3673-3679

  Moraska, Amanda R ^a   Sood, Amit ^a   Dakhil, Shaker R ^a   Sloan, Jeff A ^a   Barton, Debra ^a   Atherton, Pamela J ^a   Suh, Jason J ^a   Griffin, Patricia C ^a   Johnson, David B ^a   Ali, Aneela ^a   Silberstein, Peter T ^a   Duane, Steven F ^a   Loprinzi, Charles L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BRIEF FATIGUE INVENTORY; CANCER FATIGUE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HEART BEAT; HUMAN; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVOUSNESS; PHASE 3 CLINICAL TRIAL; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; SLEEP DISORDER; SUBJECT GLOBAL IMPRESSION OF CHANGE; SYMPTOM EXPERIENCE DIARY; TREATMENT OUTCOME; TREMOR; VOMITING; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; MIDDLE AGED; NEOPLASM;

AGED; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77956533213     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1444     Document Type: Article

References (57)

1. Mock V, Atkinson A, Barsevick A, et al: NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) 14:151-161, 2000
2. Mock V: Fatigue management: Evidence and guidelines for practice. Cancer 92:1699-1707, 2001
3. Fulton C, Knowles G: Cancer fatigue. Eur J Cancer Care (Engl) 9:167-171, 2000
4. Gutstein HB: The biologic basis of fatigue. Cancer 92:1678-1683, 2001
5. Vogelzang NJ, Breitbart W, Cella D, et al: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey - The Fatigue Coalition. Semin Hematol 34:4-12, 1997 (Pubitemid 27319139)
6. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360, 2000
7. Chow E, Fung K, Panzarella T, et al: A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 53:1291-1302, 2002 (Pubitemid 34787867)
8. Baker F, Denniston M, Smith T, et al: Adult cancer survivors: How are they faring? Cancer 104: 2565-2576, 2005
9. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in long-term breast carcinoma survivors: A longitudinal investigation. Cancer 106:751-758, 2006 (Pubitemid 43238440)
10. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000 (Pubitemid 30106604)
11. Mitchell SA, Berger AM: Cancer-related fatigue: The evidence base for assessment and management. Cancer J 12:374-387, 2006 (Pubitemid 44564821)
12. Mitchell SA, Beck SL, Hood LE, et al: Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 11:99-113, 2007
13. Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al: Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85:2273-2277, 1999 (Pubitemid 29215569)
14. Mock V, Dow KH, Meares CJ, et al: Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24:991-1000, 1997
15. Mock V, Pickett M, Ropka ME, et al: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 9:119-127, 2001 (Pubitemid 32390840)
16. Windsor PM, Nicol KF, Potter J: A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101:550-557, 2004 (Pubitemid 38970606)
17. Schwartz AL, Mori M, Gao R, et al: Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc 33: 718-723, 2001 (Pubitemid 32336630)
18. Spiegel D, Bloom JR, Yalom I: Group support for patients with metastatic cancer: A randomized outcome study. Arch Gen Psychiatry 38:527-533, 1981 (Pubitemid 11121060)
19. Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al: The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs 23:277-285, 2000 (Pubitemid 30609813)
20. Jacobsen PB, Meade CD, Stein KD, et al: Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 20:2851-2862, 2002 (Pubitemid 34651514)
21. Given C, Given B, Rahbar M, et al: Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. J Clin Oncol 22:507-516, 2004 (Pubitemid 41085798)
22. Bower JE: Cancer-related fatigue: Links with inflammation in cancer patients and survivors. Brain Behav Immun 21:863-871, 2007
23. Challman TD, Lipsky JJ: Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 75:711-721, 2000 (Pubitemid 30441501)
24. Hurd YL, Ungerstedt U: In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 166:251-260, 1989
25. Volkow ND, Wang GJ, Fowler JS, et al: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331, 1998 (Pubitemid 28471187)
26. Volkow ND, Ding YS, Fowler JS, et al: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52:456-463, 1995
27. Ferris RM, Tang FL: Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of I-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 210:422-428, 1979 (Pubitemid 10226347)
28. Gatley SJ, Pan D, Chen R, et al: Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58: 231-239, 1996 (Pubitemid 126352709)
29. Fernandez F, Adams F, Holmes VF, et al: Methylphenidate for depressive disorders in cancer patients: An alternative to standard antidepressants. Psychosomatics 28:455-461, 1987 (Pubitemid 18039023)
30. Homsi J, Nelson KA, Sarhill N, et al: A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 18:403-407, 2001
31. Mulhern RK, Khan RB, Kaplan S, et al: Shortterm efficacy of methylphenidate: A randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 22:4795-4803, 2004
32. Thompson SJ, Leigh L, Christensen R, et al: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 19:1802-1808, 2001
33. Wilwerding MB, Loprinzi CL, Mailliard JA, et al: A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 3:135-138, 1995
34. Westberg J, Gobel BH: Methylphenidate use for the management of opioid-induced sedation. Clin J Oncol Nurs 8:203-205, 2004
35. Reissig JE, Rybarczyk AM: Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 39:727-731, 2005 (Pubitemid 40396629)
36. Corey PJ, Heck AM, Weathermon RA: Amphetamines to counteract opioid-induced sedation. Ann Pharmacother 33:1362-1366, 1999 (Pubitemid 30022815)
37. Bruera E, Chadwick S, Brenneis C, et al: Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 71:67-70, 1987 (Pubitemid 17003435)
38. Bruera E, Driver L, Barnes EA, et al: Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol 21:4439-4443, 2003 (Pubitemid 46621822)
39. Meyers CA, Weitzner MA, Valentine AD, et al: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522-2527, 1998 (Pubitemid 28309050)
40. Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol Nurs Forum 29:E85-E90, 2002
41. Sarhill N, Walsh D, Nelson KA, et al: Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study. Am J Hosp Palliat Care 18:187-192, 2001
42. Bruera E, Valero V, Driver L, et al: Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial. J Clin Oncol 24:2073-2078, 2006 (Pubitemid 46622117)
43. de la Cruz M, Hui D, Parsons HA, et al: Placebo and nocebo effects in randomized doubleblind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 116:766-774, 2010
44. Lower EE, Fleishman S, Cooper A, et al: Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. J Pain Symptom Manage 38:650-662, 2009
45. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
46. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999 (Pubitemid 29115600)
47. Ware JE Jr, Sherbourne CD: The MOS 36- item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483, 1992
48. Grunberg SM, Groshen S, Steingass S, et al: Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 5:65-72, 1996 (Pubitemid 26100504)
49. Wewers ME, Lowe NK: A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13:227-236, 1990
50. Hyland ME, Sodergren SC: Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Qual Life Res 5:469-480, 1996 (Pubitemid 26382281)
51. Buysse DJ, Reynolds CF 3rd, Monk TH, et al: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 28:193-213, 1989 (Pubitemid 19144991)
52. Guyatt GH, Osoba D, Wu AW, et al: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371-383, 2002 (Pubitemid 34260746)
53. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocol development/electronic-applications/docs/ ctcaev3.pdf/
54. Revicki D, Hays RD, Cella D, et al: Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102-109, 2008
55. Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported questionnaire data: Another step toward consensus. J Clin Epidemiol 58: 1217-1219, 2005 (Pubitemid 41608536)
56. Masand PS, Tesar GE: Use of stimulants in the medically ill. Psychiatr Clin North Am 19:515-547, 1996 (Pubitemid 26277190)
57. http://www.concerta.net/adult/adult-index.html